Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BH-30236 |
| Synonyms | |
| Therapy Description |
BH-30236 inhibits CLK1/2/4, DYRK1A/B, DYRK2, PIM3, and FLT3, potentially resulting in decreased tumor cell growth (Cancer Res (2024) 84 (6_Supplement): 617). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BH-30236 | BH 30236|BH30236 | DYRK1A Inhibitor 5 DYRK1B Inhibitor 4 FLT3 Inhibitor 69 PIM3 Inhibitor 2 | BH-30236 inhibits CLK1/2/4, DYRK1A/B, DYRK2, PIM3, and FLT3, potentially resulting in decreased tumor cell growth (Cancer Res (2024) 84 (6_Supplement): 617). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06501196 | Phase I | BH-30236 + Venetoclax BH-30236 | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |